Company / Profit Margin
ELITE PHARMACEUTICALS INC /NV/ Profit Margin History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-5.1%
FY2024
5-year range
-5.1% / 35.5%
FY2020-FY2024
Trend
-114.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Profit Margin has fluctuated over the past 9 years, ranging from -122.6% in FY2018 to 39.5% in FY2016.
Based on SEC 10-K filings.
-5.1% in FY2024 with a 5-year CAGR of +7.3%.
Declined from 10.4% to -5.1% over the past 2 years.
Profit Margin over time
Growth rates
- 3-Year Change
- -32.7pp
- 5-Year Change
- +7.3pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, profit margin decreased 114.4% year-over-year.
- Peak profit margin was recorded in FY2016.
- Lowest profit margin in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -5.1% | -114.4% |
| FY2023 | 35.5% | +240.5% |
| FY2022 | 10.4% | -62.2% |
| FY2021 | 27.6% | +37.6% |
| FY2020 | 20.1% | +261.0% |
| FY2019 | -12.4% | +89.8% |
| FY2018 | -122.6% | -148.9% |
| FY2017 | -49.3% | -224.6% |
| FY2016 | 39.5% | +824.2% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026